I Have Had A Stroke Card

CEUTA EYES: Encapsulated Cell Technology (ECT) FOR DRY MACULAR DEGENERATION EYE OPHTHALMOLOGY

* *

* *
*







http://www.neurotechusa.com/ect/about_encapsulated_cell_technology.asp

Encapsulated Cell Technology (ECT), developed by the company Neurotech (Rhode Island) has managed to keep the vision in the vast majority of patients who participated in Phase II clinical trial conducted for the treatment of degeneration Macular Seca.
*
So far there is no effective treatment for dry AMD, a leading cause of blindness in people over 55 in developed countries.
*
The 96.3% of patients receiving high dose treatment have maintained stable vision after a follow up of 12 months, although it is the patients with better acuity initial visual (2 / 3 or more) that have benefited most.
*
Patients with stable vision have also developed a thickening of their retinas, which seems aumeto translate a density of photoreceptors. * ECT
The implant is a small device (about the size of a grain of rice) contains cells capable of providing consistently and continuously called ciliary neurotrophic factor protein involved in stabilizing macular.
*
Preclinical studies have been funded by the Foundation Fighting Blindness, like esudios maintains phase II / III for treatment of retinitis pigmentosa, Usher syndrome and coroidemia.
*
The results of these trials will be announced at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) meeting in the month of May in Fort Lauderdale (Florida).
*
View previous post:

http://ojosdeceuta.blogspot.com/2007/01/estado-del-tratamiento-de-la.html
*
Basic Information and Guidance. For a custom Info consult your ophthalmologist.
*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira